2025-01-16 04:24:08 pm | Source: Motilal Oswal Financial Services Ltd
Buy Sun Pharma Ltd For Target Rs. 2230 by Motilal Oswal Financial Services Ltd
* Expect growth of 10% YoY (adj. for milestone income in 3QFY24) to USD302m in the specialty segment for the quarter.
* Expect DF sales to grow 12% YoY for the quarter.
* Clarity on the launch of Deuruxolitinib in the US market and watch out for the launch in other global markets.
* Outlook on branded generics in emerging/ROW markets.
* Any update on the clinical trials of products under development.
For More Research Reports : Click Here
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Food prices to rise further globally if West Asia cr...
Delivering around 28 lakh LPG cylinders daily, no sh...
India, South Korea ink pact to boost shipbuilding sk...
Japan sets up special cell to boost FDI flows into I...
Naval Chief outlines INS Taragiri as emblem of advan...
China`s AI growth raises security, economic concerns
India`s passenger vehicle, tractor sectors show robu...
South Korea, France vow closer cooperation in AI, qu...
Telangana aims to become textile capital of South As...
India, Australia launch 'AgriMaitri' talks to co-des...
